Halichondrin B
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Halichondrin B is a polyether macrolide originally isolated from the marine sponge Halichondria okadai by Hirata and Uemura in 1986. In that report, the authors described the purification, chemical structure and exquisite anticancer activity of halichondrin B against murine cancer cells in vitro and murine tumor models in vivo.
Shortly thereafter, the Developmental Therapeutics Program (DTP) at the U.S. National Cancer Institute (NCI) designated halichondrin B a high priority for development as a novel anticancer drug. In 1991, halichondrin B was the original test case for identification of mechanism of action (in this case, tubulin-targeted mitotic inhibitor) by NCI's then-brand-new 60-cell line screen.
In 1992, it was discovered that halichondrin B's anticancer activity resided in its so-called "Right Half" macrocyclic lactone moiety (C1-C38), which represents about 2/3 of the size of the full halichondrin B molecule.
Halichondrin B is a polyether macrolide originally isolated from the marine sponge Halichondria okadai by Hirata and Uemura in 1986. In that report, the authors described the purification, chemical structure and exquisite anticancer activity of halichondrin B against murine cancer cells in vitro and murine tumor models in vivo.
Shortly thereafter, the Developmental Therapeutics Program (DTP) at the U.S. National Cancer Institute (NCI) designated halichondrin B a high priority for development as a novel anticancer drug. In 1991, halichondrin B was the original test case for identification of mechanism of action (in this case, tubulin-targeted mitotic inhibitor) by NCI's then-brand-new 60-cell line screen.
In 1992, it was discovered that halichondrin B's anticancer activity resided in its so-called "Right Half" macrocyclic lactone moiety (C1-C38), which represents about 2/3 of the size of the full halichondrin B molecule.
Biosynthesis
While a producer organism for halichondrin B has never been isolated in pure culture, the structural features of halichondrin B, such as the 'odd-even' rule of methylation, and the abundance of oxygen heterocycles, suggest it is a product of dinoflagellate polyether metabolism In support of this conjecture, the known dinoflagellate toxin okadaic acid was isolated from the same species of sponge. Yet, halichondrin B is not found in the geographically and relatively phylogenetically close sponges H. panicea or H. japonica which are found in similar tide pools in Japan as Halichondria okadai.
In constrast, halichondrins have been reported from geographically and phylogenetically distant sponges to Halichondria okadai, including Axinella sp., Phakellia carteri, and Lissodendoryx. Aquaculture of the New Zealand sponge Lissodendoryx n. sp.
1 over at least 7 years, distant from its original range (at ~10 m depth near Wellington versus its native range ~90 m deep off the Kaikōura Peninsula), established it could produce halichondrin B at a relatively high yield over a time course of years, suggesting that halichondrins were being produced by vertically inherited symbionts, rather than being concentrated from a dietary source present in the environment. In fact, the bulk of halichondrin B used by the U.S. NCI for its therapeutic evaluation, was isolated from New Zealand Lissodendoryx rather than from Halichondria okadai.
See also
Altohyrtin A
Text derived from https://en.wikipedia.org/w/index.php?oldid=1369757662 under CC BY-SA 4.0; modifications have been made.